, from the [https: //www.cancer.gov/publications/dictionaries/cancer-drug/def/erdafitinib NCI Drug Dictionary]: An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert.
==Diseases for which it is used==
==History of changes in FDA indication==
*4/12/2019: Accelerated approval for patients with locally advanced or metastatic [[Bladder_cancer|urothelial carcinoma]]
, with susceptible FGFR3 or FGFR2 genetic alterations , that has progressed during or following platinum-containing chemotherapy , including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
==Also known as==